So I, you know, I've had quite a few patients on Brenzo in the phase 2 and phase 2 trials and the post-trial access period, and now in the last couple of months after it's been approved. Um, the, the things I look for are, you know, obviously reduction in exacerbation. That's not something you can just assess right away. That's something that, you know, comes with following the patient for 6 to 12 months. Um. You know, but I, I'll tell you the things that I noted as an investigator right away in the trials was that some patients just told you that they feel better and they feel less congested. And so something I, I monitor pretty closely with my patients is just that, the quality of life. We actually do do the quality of life bronchiectasis questionnaire, um, in clinic with some of our patients. But, but beyond that, you can just ask them, you know, tell me about your cough, tell me about your sputum, tell me about your congestion. And they'll tell you if it's changed or not. Um, I do see this group of people on this drug, um, that, that will tell you they, they feel, uh, cleaner, quote unquote, or less congested. Um, not everyone does, of course, but, but again, that, that's one thing that I'm assessing kind of on a short-term basis. Long term, You know, again, I, we mentioned the FEV1, that's something I think that, that can be monitored long term, but I don't expect that to be something that you're gonna see much benefit, um, you know. Until 6, 12 months or longer being on the, the, on the medicine. But, you know, flare ups, you know, did they go through this winter without their usual, um, need for antibiotics, that kind of thing. So, I mean, you know, I think the first, I think a lot of people will be put on this medicine and you're going to see how it goes for 6 to 12 months, um, and then probably make a call as to whether you should keep doing it or not. But, but certainly some people go, On it and they feel better, and that quality of life is real important. I mean, that's, there's two reasons to treat this disease. Uh, you know, it's to diminish or, you know, mitigate the progression of lung damage, and it's to make people feel better. Um, so if you can do both, that's fantastic. If you can do one of them, that's good. Um, but those are the things we're monitoring.
Presenter
